Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Jan 21

PMID 35053199

Authors

Jianhao Liu

Ruogang Zhao

Xiaowen Jiang

Zhaohuan Li

Bo Zhang

Affiliations

Soon will be listed here.

Abstract

Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug Administration. It can bind to the amino acid residues of the 26S proteasome, thereby causing the death of tumor cells. BTZ plays an irreplaceable role in the treatment of mantle cell lymphoma and multiple myeloma. Moreover, its use in the treatment of other hematological cancers and solid tumors has been investigated in numerous clinical trials and preclinical studies. Nevertheless, the applications of BTZ are limited due to its insufficient specificity, poor permeability, and low bioavailability. Therefore, in recent years, different BTZ-based drug delivery systems have been evaluated. In this review, we firstly discussed the functions of proteasome inhibitors and their mechanisms of action. Secondly, the properties of BTZ, as well as recent advances in both clinical and preclinical research, were reviewed. Finally, progress in research regarding BTZ-based nanoformulations was summarized.

Citing Articles

The potential link between the development of Alzheimer's disease and osteoporosis.

Nasme F, Behera J, Tyagi P, Debnath N, Falcone J, Tyagi N Biogerontology. 2025; 26(1):43.

PMID: 39832071 DOI: 10.1007/s10522-024-10181-z.

Pharmaceutical Agents for Targeting Autophagy and Their Applications in Clinics.

Kench U, Sologova S, Smolyarchuk E, Prassolov V, Spirin P Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458996 PMC: 11510022. DOI: 10.3390/ph17101355.

Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma.

Kodera Y, Iguchi T, Kato D, Ikeda N, Shinada M, Aoki S J Vet Med Sci. 2024; 86(9):961-965.

PMID: 39034152 PMC: 11422692. DOI: 10.1292/jvms.23-0094.

Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor.

Tiburcio P, Chen K, Xu L, Chen K bioRxiv. 2024; .

PMID: 38948702 PMC: 11212905. DOI: 10.1101/2024.06.11.598518.

Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma.

Yuan S, Li Q, He C, Bing M, Zhang X, Xu H Blood Adv. 2024; 8(18):4886-4899.

PMID: 38875465 PMC: 11421322. DOI: 10.1182/bloodadvances.2023012464.

References

Berkers C, Verdoes M, Lichtman E, Fiebiger E, Kessler B, Anderson K . Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005; 2(5):357-62. DOI: 10.1038/nmeth759. View

Scagliotti G, Germonpre P, Bosquee L, Vansteenkiste J, Gervais R, Planchard D . A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer. 2009; 68(3):420-6. DOI: 10.1016/j.lungcan.2009.07.011. View

Liu Y, Bhattarai P, Dai Z, Chen X . Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2018; 48(7):2053-2108. PMC: 6437026. DOI: 10.1039/c8cs00618k. View

Granato M, Romeo M, Tiano M, Santarelli R, Gonnella R, Gilardini Montani M . Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy. Sci Rep. 2017; 7(1):13052. PMC: 5638868. DOI: 10.1038/s41598-017-13533-7. View

Wang M, Cai X, Yang J, Wang C, Tong L, Xiao J . A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors. ACS Appl Mater Interfaces. 2018; 10(48):41003-41011. DOI: 10.1021/acsami.8b07527. View

Pohl C, Dikic I . Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019; 366(6467):818-822. DOI: 10.1126/science.aax3769. View

Johnson D . The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer. 2014; 22(1):T1-17. PMC: 4170053. DOI: 10.1530/ERC-14-0005. View

Wang N, Chen M, Wang T . Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization. J Control Release. 2019; 303:130-150. PMC: 7111479. DOI: 10.1016/j.jconrel.2019.04.025. View

Raninga P, Lee A, Sinha D, Dong L, Datta K, Lu X . Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics. 2020; 10(12):5259-5275. PMC: 7196287. DOI: 10.7150/thno.42705. View

10.

Mahmoudian M, Valizadeh H, Zakeri-Milani P . Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation. Drug Dev Ind Pharm. 2018; 44(10):1598-1605. DOI: 10.1080/03639045.2018.1483385. View

11.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

12.

Fennell D, Chacko A, Mutti L . BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene. 2007; 27(9):1189-97. DOI: 10.1038/sj.onc.1210744. View

13.

Gu Z, Wang X, Cheng R, Cheng L, Zhong Z . Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma. Acta Biomater. 2018; 80:288-295. DOI: 10.1016/j.actbio.2018.09.022. View

14.

Bedford L, Lowe J, Dick L, Mayer R, Brownell J . Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2010; 10(1):29-46. PMC: 7097807. DOI: 10.1038/nrd3321. View

15.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

16.

Sun H, Meng F, Cheng R, Deng C, Zhong Z . Reduction-sensitive degradable micellar nanoparticles as smart and intuitive delivery systems for cancer chemotherapy. Expert Opin Drug Deliv. 2013; 10(8):1109-22. DOI: 10.1517/17425247.2013.783009. View

17.

Singh A, Palladino M, Lloyd G, Potts B, Chauhan D, Anderson K . Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 2010; 149(4):550-9. PMC: 4427841. DOI: 10.1111/j.1365-2141.2010.08144.x. View

18.

Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-92. DOI: 10.1016/s1535-6108(02)00127-7. View

19.

Liu Y, Dai Z, Wang J, Tu Y, Zhu L . Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment. Chem Commun (Camb). 2019; 55(29):4254-4257. PMC: 6543544. DOI: 10.1039/c9cc01344j. View

20.

Hendil K, Kriegenburg F, Tanaka K, Murata S, Lauridsen A, Johnsen A . The 20S proteasome as an assembly platform for the 19S regulatory complex. J Mol Biol. 2009; 394(2):320-8. DOI: 10.1016/j.jmb.2009.09.038. View